Biotricity (BTCY) investor relations material

Company overview and business model

• Focuses on biometric data monitoring solutions for medical, healthcare, and consumer markets, with an emphasis on cardiac diagnostics and chronic disease management.

• Generates recurring revenue through utilization-based technology fees, targeting hospitals, clinics, and physician offices.

• Commercialized FDA-cleared Bioflux and Biocore (formerly Biotres) devices, expanding to 35 states and planning further US and international growth.

• Business model leverages an insourcing approach, enabling providers to use proprietary technology and bill for services, differentiating from outsourced competitors.

• Expanding product ecosystem includes Bioheart (consumer heart monitor), Biocare (chronic care management), and Biokit (remote patient monitoring kit).

Financial performance and metrics

• Fiscal year ended March 31, 2025: revenue of $13.8M, up 14.3% from prior year; gross profit margin increased to 76.6%.

• Net loss attributable to common stockholders was $11.9M, improved from $14.9M in the prior year.

• Operating expenses decreased to $13.0M from $17.2M, reflecting cost control initiatives.

• Cash balance as of March 31, 2025 was $0.4M; working capital deficit of $16M; accumulated deficit of $139M.

• Six months ended September 30, 2025: revenue of $7.8M (20% YoY growth), gross margin 81.2%, positive operating cash flow for the second consecutive quarter.

Use of proceeds and capital allocation

• Intends to use net proceeds from the offering for working capital and general corporate purposes.

• Management has broad discretion over the use of proceeds; funds may be allocated to corporate purposes that may not directly improve operating results.